COVID-19 Clinical Trials: A Primer for the Cardiovascular and Cardio-Oncology Communities

Mostrar otras versiones (1)

The coronavirus disease-2019 (COVID-19) pandemic has resulted in a proliferation of clinical trials designed to slow the spread of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). Many therapeutic agents that are being used to treat patients with COVID-19 are repurposed treatments for i...

Descripción completa

Detalles Bibliográficos
Autores principales: Ky, Bonnie, Mann, Douglas L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
State-of-the-Art Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7164888/
https://www.ncbi.nlm.nih.gov/pubmed/32313885
http://dx.doi.org/10.1016/j.jaccao.2020.04.002
Descripción
Sumario:The coronavirus disease-2019 (COVID-19) pandemic has resulted in a proliferation of clinical trials designed to slow the spread of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). Many therapeutic agents that are being used to treat patients with COVID-19 are repurposed treatments for influenza, Ebola, or for malaria that were developed decades ago and are unlikely to be familiar to the cardiovascular and cardio-oncology communities. Here, we provide a foundation for cardiovascular and cardio-oncology physicians on the front line providing care to patients with COVID-19, so that they may better understand the emerging cardiovascular epidemiology and the biological rationale for the clinical trials that are ongoing for the treatment of patients with COVID-19.

Ejemplares similares